SEC Form 4	
------------	--

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

1. Name and Address of Reporting Person [*] <u>Kowolenko Michael</u>			2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]		ationship of Reporting Pe < all applicable) Director Officer (give title	erson(s) to Issuer 10% Owner Other (specify
(Last) (First) (Middle) 14 CAMBRIDGE CENTER		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/25/2007		below) SVP, Pharm Ops 8	below)
(Street) CAMBRIDGE	МА	02142	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	vidual or Joint/Group Fili Form filed by One Re Form filed by More th	porting Person
(City)	(State)	(Zip)			Person	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	07/25/2007		M ⁽¹⁾		3,450	A	\$42.12	21,573.856 ⁽²⁾	D		
Common Stock	07/25/2007		M ⁽¹⁾		4,356	A	\$37.45	25,929.856	D		
Common Stock	07/25/2007		M ⁽¹⁾		8,438	Α	\$43.5	34,367.856	D		
Common Stock	07/25/2007		M ⁽¹⁾		4,263	A	\$44.24	38,630.856	D		
Common Stock	07/25/2007		S ⁽¹⁾		20,507	D	\$ <mark>58</mark>	18,123.856	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(e.g., puts, tails, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) (Disp of (I	oosed 0) tr. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to buy)	\$42.12	07/25/2007		M ⁽¹⁾			3,450	(3)	04/01/2012	Common Stock	3,450	(4)	3,450	D	
Stock Option (Right to buy)	\$37.45	07/25/2007		M ⁽¹⁾			4,356	(5)	12/06/2012	Common Stock	4,356	(4)	4,355	D	
Stock Option (Right to buy)	\$43.5	07/25/2007		M ⁽¹⁾			8,438	(6)	02/06/2014	Common Stock	8,438	(4)	14,062	D	
Stock Option (Right to buy)	\$44.24	07/25/2007		M ⁽¹⁾			4,263	(7)	02/06/2016	Common Stock	4,263	(4)	29,837	D	

Explanation of Responses:

1. Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

2. Includes 117.9266 shares acquired on March 30, 2007 and 39.4994 shares acquired on June 29, 2007 under the Biogen Idec Inc. Employee Stock Purchase Plan.

3. The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 04/01/02.

4. Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).

5. The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 12/06/02.

6. The stock options become exercisable in four (4) equal annual installments on 12/31/04, 12/31/05, 12/31/06 and 12/31/07.

7. The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/06/06.

Remarks:

Robert A. Licht, Attorney in Fact for Michael Kowolenko

07/27/2007

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.